KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell lymphoma including through use in the community setting ...

The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a ...

Title: CRISPR/Cas-mediated APOC3 Knockout as a One-time Treatment for Severe Hypertriglyceridemia Presenters: Alan Brooks, PhD, Senior Vice President of Research at Metagenomi Date/time: Monday, ...

To compete at iGEM, a sort of science Olympics, teens at a Georgia high school set their sights on finding a better way to ...

But sometimes, this top investor who focuses on innovation does see eye-to-eye with analysts, and the perfect example of this ...

It might be time to look a bit off the beaten path, at names that can stand up to any AI-stock-led correction.

Following the weekend data presentation, Citizens voiced optimism regarding CRISPR’s in-vivo projects. The firm noted some ...

CRISPR-based gene editing has revolutionized modern biology, but these tools are unable to access the DNA that resides inside ...

As reported in the Wall Street Journal, Armstrong has now officially entered the designer-baby business by funding heritable ...

Highlighting 10 innovative late-stage BioPharma drugs with the potential to reshape treatment paradigms and industry dynamics ...

Gene-edited crops are no safer than GMOs, and fast-tracking regulatory approval could trigger a costly backlash.

New research breaks down how scientists use CRISPR technology to lower cholesterol. The cholesterol-lowering effects could be permanent.